GW Pharmaceuticals PLC Directorate Change (2262Y)
February 19 2013 - 9:16AM
UK Regulatory
TIDMGWP
RNS Number : 2262Y
GW Pharmaceuticals PLC
19 February 2013
GW Appoints Cabot Brown as a Non-Executive Director
Porton Down, UK; February 19 2013:GW Pharmaceuticals plc
(AIM:GWP) today announces the appointment of Cabot Brown as a
non-executive director with immediate effect. Mr Brown will sit on
the Nominations Committee, Audit Committee, as well as the
Remuneration Committee.
Cabot Brown, aged 51, has more than 30 years of experience in
the financial industry specialising in the health care sector. Mr
Brown is the founder of Carabiner LLC, an advisory and private
equity firm based in San Francisco and London that specializes in
health care and education. Previously, Mr Brown served as a
Managing Director at GCA Savvian, an international financial
advisory firm, where he directed the firm's efforts in the health
care industry. Before joining GCA Savvian in 2011, Mr Brown worked
for ten years at Seven Hills Group, an investment banking group
based in San Francisco, of which he was a co-founder and where he
directed the firm's health care activities. Prior to Seven Hills,
he was Managing Director of Brown, McMillan & Co., a U.S.
investment firm he co-founded that sponsored buy-outs and venture
capital investments.
From 1987 until 1995, Mr Brown worked at Volpe, Welty &
Company, a U.S. investment bank, where he co-founded and ran the
health care practice and served as a member of its Executive
Committee. Mr Brown started his finance career in New York, working
in the investment banking departments of The First Boston
Corporation and Lehman Brothers. Mr Brown holds an M.B.A. from
Harvard Business School with high distinction as a George F. Baker
Scholar and an A.B. cum laude in Government from Harvard
College.
Dr Geoffrey Guy, Chairman, said, "We are very pleased to welcome
Cabot to the Board. Having spent 25 years in investment banking in
the United States providing strategic financial advice to companies
in the health care sector, Cabot brings a wealth of valuable
expertise to our Board. In particular, we see the United States as
a country of increasing importance to the future of our business as
we move towards completion of the pivotal Phase III cancer pain
trials programme in that country for our lead product, Sativex(R) .
We look forward to benefiting from Cabot's experience and advice in
the years ahead."
The following disclosures are made in accordance with AIM rule
17 and Schedule 2 paragraph (g) of the AIM rules:
Cabot Brown has been a Director/Partner of the following
companies in the previous five years:
GCA Savvian Advisors, Managing Director
Seven Hills Group LLC, Managing Director, Board of Advisors
Brown, McMillian & Co., Managing Director
Until 1979, Cabot Brown was called Stephen Cabot Brown, Jr.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 7831
3113
Dr Geoffrey Guy, Chairman (Thereafter) +44
1980 557000
Justin Gover, Managing Director
FTI Consulting +44 20 7831 3113
Ben Atwell / John Dineen
Peel Hunt LLP +44 207 418 8900
James Steel / Vijay Barathan
Notes to Editors:
About GW
GW was founded in 1998 and listed on the AIM, a market of the
London Stock Exchange, in June 2001. Operating under license from
the UK Home Office, the company researches and develops cannabinoid
pharmaceutical products for patients who suffer from a range of
serious ailments, in particular multiple sclerosis and cancer pain.
GW has assembled a large in-house scientific team with expertise in
cannabinoid science as well as experience in the development of
both plant-based prescription pharmaceutical products and medicines
containing controlled substances. GW occupies a world leading
position in cannabinoids and has developed an extensive
international network of the most prominent scientists in the
field. For further information, please visit www.gwpharm.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOABUGDDUBBBGXC
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024